Tagged with ess

Romania Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the organisational changes in the last year, and how they have been inducive to double-digit growth for Takeda. Additionally, she reveals…

UAE With a combined experience of over five decades in the pharmaceutical industry including senior executive roles at companies such as Merck and Janssen, Karim Smaira and Kamel Ghammachi have come a long way with Genpharm, the Dubai-based market access company they founded in 2012. After years of learning the ins…

Romania Dan Zaharescu, executive director of the Romanian Association of Pharmaceutical Manufacturers (ARPIM), shares his insights on market access, the need to reform pricing methodologies, the debate around the claw-back tax, his expectations for the newly appointed minister of health and prime minister, as well as his objectives for 2020.  …

UAE Georg Schroeckenfuchs, Novartis’ president for the Middle East and head of MEA cluster, is a 32-year veteran of the pharmaceutical industry and describes the company’s footprint within the MEA region, provides insights into its strategy of segmenting their markets into three categories. Furthermore, he discusses the company’s strategic priorities when…

Czech Republic Martin Minarovič, Janssen’s country director Czech Republic, discusses the success factors behind the company’s strong growth, not only in terms of revenue but more importantly in terms of the number of patients treated. Moreover, he highlights Janssen’s transformation to become a more customer- and patient-centric organization, the progress and areas…

Generics Arun Narayan of Medicines for Europe’s Value Added Medicines Group has been working to promote the benefits of value added medicines and how real-world evidence must be considered. In a recent interview with PharmaBoardroom he elaborated on what some countries are already doing to adopt Value Added Medicines and the…

Czech Republic Emelie Antoni joined AstraZeneca in Sweden 20 years ago, evolving in global, regional and local roles. Last year, she became country manager for Czech Republic & Slovakia, with an ambitious plan to triple revenues during her tenure. She lays down the pillars of her plan, discusses the evolving role of…

Generics Arun Narayan is the Chairman of the Value Added Medicines Sector Group at Medicines for Europe, in addition to serving as Head of Global Portfolio Strategy and Head of European Business Operations at Mylan. Narayan introduces compelling reasons why payers in Europe should consider Value Added Medicines, including cost savings…

Belgium The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC), Lung Cancer Europe (LuCE), and Digestive Cancers Europe (DiCE), the theme of this year’s event was “Towards A New Era…

Taiwan Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for pharma multinationals implanted in Taiwan give their first impressions of the market and what recommends it.    NHI: Bringing the…

Hungary Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop science – soon to integrate Monsanto. As a leader with unique experience in finance, Ms Kárpát offers her insights into…

Hungary In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of Health Insurance Fund Management (NEAK), explains, this has already had a significant impact on patient access to innovative new products.…